Dendritic cells transfected with a polyepitope DNA construct stimulate an antitumor cytotoxic response in various tumors

Mol Clin Oncol. 2022 Oct 3;17(5):155. doi: 10.3892/mco.2022.2588. eCollection 2022 Nov.

Abstract

Dendritic cells (DCs) loaded with tumor-associated antigens (TAAs) are known to be crucial for the antitumor response and are still included in various treatment regimens in cancer immunotherapy research. In the present study, a cell-based protocol was evaluated, involving the use of original DNA constructs encoding the wide range of TAA epitopes expressed on different epithelial cancers. The constructs were transfected into in vitro-generated DCs of patients with various types of cancer, including breast, colorectal and non-small cell lung cancer. The direct cytotoxicity assay of effector cells, activated with the transfected DCs, revealed a significant increase in cytotoxicity against autologous tumor cells. The use of DNA constructs encoding a large number of TAAs for insertion into DCs in vitro, aiming to activate a T-cell response may prove to be a reliable and unified approach for immunotherapy and for the prevention of relapse in patients with epithelial cancers.

Keywords: T-cells; cytotoxicity; dendritic cells; epithelial cancer; polyepitope DNA construct.

Grants and funding

Funding: The present study was funded by the Russian Science Foundation grant no. 21-65-00004, https://rscf.ru/project/21-65-00004/.